Abstract: The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or suspected to contain lymphocytes; or (b) culturing lymphocytes, which lymphocytes are isolated from a tissue or blood sample from a subject; wherein the lymphocytes are expanded in a culture medium in which at least one of the following parameters is monitored and adjusted to a predefined value or range: pH, dissolved oxygen (DO) concentration, glucose concentration, lactate concentration and/or temperature; and wherein the method comprises a step of adjusting the culture volume to the expansion rate of the lymphocytes.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: This disclosure describes novel T cell receptors (TCRs) specific for tumor-associated antigens (TAAs) and methods of use thereof. The disclosed TCRs and methods of use expand the applications of adoptive cell therapy and TCR-based cellular immunotherapies.

Abstract: The present invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, at least 20% are CD27/CD28 double positive and less than 10% are triple positive for CD45RA, CD57 and KLRG1 and a method for expansion of a population of lymphocytes specific for one or more antigens comprising a single culture phase.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.

Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.